We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

An Endothelial-Specific MicroRNA Regulates Embryonic Angiogenesis

By LabMedica International staff writers
Posted on 21 Aug 2008
A recent publication described a mechanism employed by the developing embryo to regulate formation of blood vessels.

Investigators at the University of Texas Southwestern Medical Center (Dallas, TX, USA) examined the role of endothelial cells, and in particular the role of an endothelial cell-specific microRNA, in the process of angiogenesis.

To this end, the investigators genetically engineered a line of mice to lack the microRNA miR-126. They reported in the August 12, 2008, online edition of the journal Developmental Cell that targeted deletion of miR-126 in mice caused leaky vessels, hemorrhaging, and partial embryonic lethality, due to a loss of vascular integrity and defects in endothelial cell proliferation, migration, and angiogenesis. In this study, more than 40% of embryos lacking miR-126 failed to survive. Those that were born seemed normal but found less able to recover from simulated heart attack. Almost all mice lacking miR-126 died within three weeks of induced myocardial infarction, while more than 70% of control mice survived for at least three weeks.

At the molecular level miR-126 apparently enhanced the proangiogenic actions of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) and promoted blood vessel formation by repressing the expression of Spred-1, an intracellular inhibitor of angiogenic signaling.

"MicroRNA research represents a new frontier in understanding and treating human disease. This is just a hint of what can come,” said senior author Dr. Eric Olson, professor of molecular biology at the University of Texas Southwestern Medical Center. "Manipulating this microRNA provides a completely new way of addressing cardiovascular disorders.”

Related Links:
University of Texas Southwestern Medical Center


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
21 Aug 2008  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
21 Aug 2008  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
21 Aug 2008  |   BioResearch